Traws Pharma Inc. – Filings and Transcripts

NASDAQ: TRAW
Share price (3/26/26): $1.93
Market cap (3/26/26): $15.4 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024 – amended

ended 12/31/24 FY 2024

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement

Shelf registration

Prospectus supplement with pricing info

Ownership Filter

Redfield Robert

Pauza Charles David

Savchuk Nikolay

Clarke Trafford

Shoemaker Mary Teresa

News Filter

PK Study of Compressed Tivoxavir Marboxil Tablets Submitted Under Open IND in Australia and Preparations Are Underway for a Human Influenza Prophylaxis Challenge Study in the UK

Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Reports Positive Interim Clinical Data With Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Change in Directors, Officers or Compensation

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Preliminary proxy

Definitive proxy

Other Filter

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission